A Phase II trial evaluated the safety, efficacy and side-effect profile of three different dosing regimens of the albiglutide. This was a randomized, double-blind trial enrolling 356 subjects with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback